Vertex adds to public reimbursement agreement for Trikafta in Canada
magicmine/iStock via Getty Images


Vertex Pharmaceuticals (NASDAQ:VRTX) has amended a letter of intent with the pan-Canadian Pharmaceutical Alliance regarding the public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis.
A prior letter of intent was for patients 12 years and older. The amended version covers the treatment for those six years and older. The Canadian Agency for Drugs and Technology in Health has issued a positive clinical recommendation for the younger age group.

Vertex (VRTX) said it would work with public drug plans to ensure eligible people with cystic fibrosis have access to Trikafta.
Seeking Alpha's Quant Rating views Vertex (VRTX) as a strong buy with particularly strong grades for profitability, momentum, and growth.